Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
10 03 2020
Historique:
entrez: 12 3 2020
pubmed: 12 3 2020
medline: 12 3 2021
Statut: epublish

Résumé

Each year, >180,000 infants become infected via mother-to-child transmission (MTCT) of HIV despite the availability of effective maternal antiretroviral treatments, underlining the need for a maternal HIV vaccine. We characterized 224 maternal HIV envelope (Env)-specific IgG monoclonal antibodies (MAbs) from seven nontransmitting and transmitting HIV-infected U.S. and Malawian mothers and examined their neutralization activities against nontransmitted autologous circulating viruses and infant-transmitted founder (infant-T/F) viruses. Only a small subset of maternal viruses, 3 of 72 (4%), were weakly neutralized by maternal linear V3 epitope-specific IgG MAbs, whereas 6 out of 6 (100%) infant-T/F viruses were neutralization resistant to these V3-specific IgG MAbs. We also show that maternal-plasma broadly neutralizing antibody (bNAb) responses targeting the V3 glycan supersite in a transmitting woman may have selected for an N332 V3 glycan neutralization-resistant infant-T/F virus. These data have important implications for bNAb-eliciting vaccines and passively administered bNAbs in the setting of MTCT.

Identifiants

pubmed: 32156815
pii: mBio.00176-20
doi: 10.1128/mBio.00176-20
pmc: PMC7064758
pii:
doi:

Substances chimiques

Broadly Neutralizing Antibodies 0
Epitopes 0
HIV Antibodies 0
HIV Envelope Protein gp120 0
HIV envelope protein gp120 (305-321) 0
Peptide Fragments 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : F31 AI127303
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI100645
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122909
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI106380
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI117915
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI131251
Pays : United States
Organisme : NICHD NIH HHS
ID : DP2 HD075699
Pays : United States

Informations de copyright

Copyright © 2020 Martinez et al.

Références

J Virol. 1995 Feb;69(2):1001-12
pubmed: 7815476
Virology. 2005 Sep 1;339(2):226-38
pubmed: 16005039
J Virol. 2005 May;79(10):6528-31
pubmed: 15858037
Pediatrics. 2000 Jan;105(1):e8
pubmed: 10617745
Nat Commun. 2018 Mar 16;9(1):1111
pubmed: 29549260
J Infect Dis. 1998 Jun;177(6):1737-41
pubmed: 9607861
Retrovirology. 2013 Jan 10;10:3
pubmed: 23305422
J Virol. 2010 Feb;84(3):1439-52
pubmed: 19939925
J Infect Dis. 1993 Jul;168(1):207-10
pubmed: 8515110
Cell. 2019 Jun 27;178(1):190-201.e11
pubmed: 31204101
Bioinformatics. 2006 Feb 15;22(4):438-44
pubmed: 16357034
J Virol. 2017 Apr 13;91(9):
pubmed: 28202762
Retrovirology. 2011 Aug 15;8:67
pubmed: 21843318
Nature. 2016 Jul 28;535(7613):556-60
pubmed: 27338952
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
Nat Med. 2019 Apr;25(4):591-596
pubmed: 30886409
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
Lancet. 1991 Feb 2;337(8736):253-60
pubmed: 1671109
Retrovirology. 2013 Oct 07;10:103
pubmed: 24099103
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
EBioMedicine. 2014 Nov 1;1(1):37-45
pubmed: 25599085
Virology. 2010 Aug 15;404(1):59-70
pubmed: 20494390
Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8
pubmed: 30629920
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298420
Int J Womens Health. 2015 Feb 03;7:171-80
pubmed: 25678822
PLoS Pathog. 2010 Aug 05;6(8):e1001028
pubmed: 20700449
Cell Host Microbe. 2015 Sep 9;18(3):354-62
pubmed: 26355218
Placenta. 1994 Jul;15(5):453-66
pubmed: 7997446
Vaccine. 2019 Jan 3;37(1):169-175
pubmed: 30454948
Cell. 2014 Jul 31;158(3):481-91
pubmed: 25065977
BMC Bioinformatics. 2010 Oct 25;11:532
pubmed: 20973976
Virology. 2013 May 10;439(2):81-8
pubmed: 23466102
Clin Infect Dis. 2010 Dec 15;51(12):1355-61
pubmed: 21058908
AIDS. 1994 Oct;8(10):1451-6
pubmed: 7818816
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
JAMA Pediatr. 2016 Sep 1;170(9):840-7
pubmed: 27380464
PLoS Pathog. 2009 Sep;5(9):e1000594
pubmed: 19763269
Curr Opin HIV AIDS. 2014 May;9(3):210-6
pubmed: 24662931
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10598-603
pubmed: 23754383
J Virol. 2014 Mar;88(5):2489-507
pubmed: 24352443
Cell Rep. 2017 Feb 28;18(9):2175-2188
pubmed: 28249163
J Virol. 2006 Jan;80(2):835-44
pubmed: 16378985
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Science. 1992 Feb 28;255(5048):1134-7
pubmed: 1546316
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Mucosal Immunol. 2015 Mar;8(2):316-26
pubmed: 25100291
Cell Host Microbe. 2012 Oct 18;12(4):396-407
pubmed: 23084910
J Clin Invest. 2015 Jul 1;125(7):2702-6
pubmed: 26053661
N Engl J Med. 2008 Oct 9;359(15):1555-64
pubmed: 18799552
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298421
PLoS Pathog. 2018 Apr 19;14(4):e1006944
pubmed: 29672607
Lancet. 1994 Feb 12;343(8894):390-1
pubmed: 7905554
J Virol Methods. 2009 Jun;158(1-2):171-9
pubmed: 19428587
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
PLoS Pathog. 2012;8(5):e1002721
pubmed: 22693447
Nat Med. 2012 Nov;18(11):1688-92
pubmed: 23086475
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Nat Commun. 2019 Jul 1;10(1):2898
pubmed: 31263112
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
Mol Biol Evol. 2010 Feb;27(2):221-4
pubmed: 19854763
mBio. 2017 Oct 24;8(5):
pubmed: 29066544

Auteurs

David R Martinez (DR)

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Duke Human Vaccine Institute, Durham, North Carolina, USA.

Joshua J Tu (JJ)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Amit Kumar (A)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Jesse F Mangold (JF)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Riley J Mangan (RJ)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Ria Goswami (R)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Elena E Giorgi (EE)

Los Alamos National Laboratory, Los Alamos, New Mexico, USA.

Juilin Chen (J)

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Duke Human Vaccine Institute, Durham, North Carolina, USA.

Michael Mengual (M)

Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Ayooluwa O Douglas (AO)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Holly Heimsath (H)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Kevin O Saunders (KO)

Duke Human Vaccine Institute, Durham, North Carolina, USA.
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

Nathan I Nicely (NI)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Joshua Eudailey (J)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Giovanna Hernandez (G)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Papa Kwadwo Morgan-Asiedu (PK)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Kevin Wiehe (K)

Duke Human Vaccine Institute, Durham, North Carolina, USA.

Barton F Haynes (BF)

Duke Human Vaccine Institute, Durham, North Carolina, USA.
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

M Anthony Moody (MA)

Duke Human Vaccine Institute, Durham, North Carolina, USA.
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.

Celia LaBranche (C)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

David C Montefiori (DC)

Duke Human Vaccine Institute, Durham, North Carolina, USA.
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

Feng Gao (F)

Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Sallie R Permar (SR)

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA sallie.permar@duke.edu.
Duke Human Vaccine Institute, Durham, North Carolina, USA.
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH